Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.0690 EUR
−103.04 M EUR
114.45 M EUR
124.81 M
About Seres Therapeutics, Inc.
Sector
Industry
CEO
Eric D. Shaff
Website
Headquarters
Cambridge
Founded
2010
FIGI
BBG009HVCRM6
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SERES THERAPEUT. DL -,001 stocks are traded under the ticker 1S9.
We've gathered analysts' opinions on SERES THERAPEUT. DL -,001 future price: according to them, 1S9 price has a max estimate of 9.47 EUR and a min estimate of 0.95 EUR. Watch 1S9 chart and read a more detailed SERES THERAPEUT. DL -,001 stock forecast: see what analysts think of SERES THERAPEUT. DL -,001 and suggest that you do with its stocks.
Yes, you can track SERES THERAPEUT. DL -,001 financials in yearly and quarterly reports right on TradingView.
SERES THERAPEUT. DL -,001 is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
1S9 earnings for the last quarter are 0.52 EUR per share, whereas the estimation was −0.07 EUR resulting in a 848.09% surprise. The estimated earnings for the next quarter are −0.19 EUR per share. See more details about SERES THERAPEUT. DL -,001 earnings.
SERES THERAPEUT. DL -,001 revenue for the last quarter amounts to 0.00 EUR, despite the estimated figure of 27.84 M EUR. In the next quarter, revenue is expected to reach 0.00 EUR.
1S9 net income for the last quarter is −52.03 M EUR, while the quarter before that showed −30.69 M EUR of net income which accounts for −69.55% change. Track more SERES THERAPEUT. DL -,001 financial stats to get the full picture.
No, 1S9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2024, the company has 233.00 employees. See our rating of the largest employees — is SERES THERAPEUT. DL -,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SERES THERAPEUT. DL -,001 EBITDA is −122.01 M EUR, and current EBITDA margin is −72.96%. See more stats in SERES THERAPEUT. DL -,001 financial statements.
Like other stocks, 1S9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SERES THERAPEUT. DL -,001 stock right from TradingView charts — choose your broker and connect to your account.